NCT00068146View on ClinicalTrials.gov

Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

September 19, 2002

Study Completion Date

November 26, 2012

Conditions

Lymphoproliferative DisordersLymphoma

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00068146 - Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma | Biotech Hunter | Biotech Hunter